Natalizumab in Crohn's disease: Results from a US tertiary inflammatory bowel disease center

Inflammatory Bowel Diseases

Volumn 19, Issue 3, 2013, Pages 621-626

  Sakuraba, Atsushi ^a   Keyashian, Kian ^a   Correia, Chase ^b   Melek, John ^c,d   Cohen, Russell D ^a   Hanauer, Stephen B ^a   Rubin, David T ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b University of Nevada School of Medicine   (United States)

^c MERCY HOSPITAL AND MEDICAL CENTER   (United States)

^d ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Biologic; Crohn's disease; Natalizumab; Safety

Indexed keywords

NATALIZUMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; COLON DISEASE; CONSTIPATION; CONTROLLED STUDY; CROHN DISEASE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; ILEUM DISEASE; LEUKOENCEPHALOPATHY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; DISCRIMINANT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS; TREATMENT OUTCOME; UNITED STATES;

EID: 84876360872     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e31827eea78     Document Type: Article

References (15)

1. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006;12:S3-S9.
2. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434.
3. Hibi T, Ogata H. Novel pathophysiological concepts of inflammatory bowel disease. J Gastroenterol. 2006;41:10-16.
4. Sakuraba A, Sato T, Kamada N, et al. Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn's disease. Gastroenterology. 2009;137:1736-1745.
5. Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord. 2003;3:81-92.
6. Hanauer SB. Review article: aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20:60-65.
7. Guessous I, Juillerat P, Pittet V, et al. Evaluating appropriateness of treatment for Crohn's disease: feasibility of an explicit approach. Digestion. 2007;75:46-52.
8. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126:402-413.
9. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
10. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333; quiz 591.
11. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005;353:1912-1925.
12. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med. 2003;348:24-32.
13. Hanauer SB. Inflammatory bowel disease. N Engl J Med. 1996;334: 841-848.
14. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology. 2007;132:1672-1683.
15. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366: 1870-1880.